Omnicell Ownership
| OMCL Stock | USD 43.20 1.78 3.96% |
Shares in Circulation | First Issued 2001-03-31 | Previous Quarter 46 M | Current Value 46.4 M | Avarage Shares Outstanding 34.7 M | Quarterly Volatility 8.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Omnicell |
Omnicell Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Omnicell has Price/Earnings To Growth (PEG) ratio of 2.28. The entity recorded a loss per share of 0.39. The firm had not issued any dividends in recent years. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. Omnicell operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 4000 people. To find out more about Omnicell contact Randall Lipps at 877 415 9990 or learn more at https://www.omnicell.com.Besides selling stocks to institutional investors, Omnicell also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Omnicell's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Omnicell's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Omnicell Quarterly Liabilities And Stockholders Equity |
|
Omnicell Insider Trades History
Only 1.63% of Omnicell are currently held by insiders. Unlike Omnicell's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Omnicell's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Omnicell's insider trades
Omnicell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Omnicell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Omnicell backward and forwards among themselves. Omnicell's institutional investor refers to the entity that pools money to purchase Omnicell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lazard Asset Management Llc | 2024-09-30 | 904.3 K | Bank Of New York Mellon Corp | 2024-09-30 | 869.3 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 862.7 K | Federated Hermes Inc | 2024-09-30 | 849.3 K | Cadian Capital Management Lp | 2024-09-30 | 800 K | Sumitomo Mitsui Trust Group Inc | 2024-09-30 | 750.5 K | Royal Bank Of Canada | 2024-09-30 | 717.7 K | Mirae Asset Global Etfs Holdings Ltd. | 2024-09-30 | 648.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 595 K | Blackrock Inc | 2024-06-30 | 8.2 M | Vanguard Group Inc | 2024-09-30 | 5.5 M |
Omnicell Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Omnicell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Omnicell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Omnicell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Omnicell Outstanding Bonds
Omnicell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Omnicell uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Omnicell bonds can be classified according to their maturity, which is the date when Omnicell has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ON SEMICONDUCTOR P Corp BondUS682189AQ81 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Omnicell Corporate Filings
F4 | 17th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 11th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.558 | Earnings Share (0.39) | Revenue Per Share 23.218 | Quarterly Revenue Growth (0.05) | Return On Assets (0.01) |
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.